Journal of Hepatology
Volume 51, Issue 5 , Pages 845-852, November 2009

Reduced serum hepcidin levels in patients with chronic hepatitis C

  • Domenico Girelli

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • Corresponding Author InformationCorresponding authors. Tel.: +39 045 8124410; fax: +39 045 8027473 (D. Girelli), tel./fax: +39 045 8124205 (G. Fattovich).
  • ,
  • Michela Pasino

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
    • Department of Anesthesiological and Surgical Sciences, University of Verona, Verona, Italy
  • ,
  • Julia B. Goodnough

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • ,
  • Elizabeta Nemeth

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • ,
  • Maria Guido

      Affiliations

    • Department of Diagnostic Sciences & Special Therapies, University of Padova, Padova, Italy
  • ,
  • Annalisa Castagna

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
  • ,
  • Fabiana Busti

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
  • ,
  • Natascia Campostrini

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
  • ,
  • Nicola Martinelli

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
  • ,
  • Italo Vantini

      Affiliations

    • Department of Biomedical and Surgical Sciences, University of Verona, Verona, Italy
  • ,
  • Roberto Corrocher

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy
  • ,
  • Tomas Ganz

      Affiliations

    • Department of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
  • ,
  • Giovanna Fattovich

      Affiliations

    • Department of Anesthesiological and Surgical Sciences, University of Verona, Verona, Italy
    • Corresponding Author InformationCorresponding authors. Tel.: +39 045 8124410; fax: +39 045 8027473 (D. Girelli), tel./fax: +39 045 8124205 (G. Fattovich).

Received 24 March 2009; received in revised form 17 June 2009; accepted 21 June 2009. published online 12 August 2009.

Associate Editor: Y.M. Deugnier

Background/Aims: Patients with chronic hepatitis C (CHC) often have increased liver iron, a condition associated with reduced sustained response to antiviral therapy, more rapid progression to cirrhosis, and development of hepatocellular carcinoma. The hepatic hormone hepcidin is the major regulator of iron metabolism and inhibits iron absorption and recycling from erythrophagocytosis. Hepcidin decrease is a possible pathophysiological mechanism of iron overload in CHC, but studies in humans have been hampered so far by the lack of reliable quantitative assays for the 25-amino acid bioactive peptide in serum (s-hepcidin).

Methods: Using a recently validated immunoassay, we measured s-hepcidin levels in 81 untreated CHC patients and 57 controls with rigorous definition of normal iron status. All CHC patients underwent liver biopsy with histological iron score.

Results: s-hepcidin was significantly lower in CHC patients than in controls (geometric means with 95% confidence intervals: 33.7, 21.5–52.9 versus 90.9, 76.1–108.4ng/mL, respectively; p<0.001). In CHC patients, s-hepcidin significantly correlated with serum ferritin and histological total iron score, but not with s-interleukin-6. After stratification for ferritin quartiles, s-hepcidin increased significantly across quartiles in both controls and CHC patients (chi for trend, p<0.001). However, in CHC patients, s-hepcidin was significantly lower than in controls for each corresponding quartile (analysis of variance, p<0.001).

Conclusions: These results, together with very recent studies in animal and cellular models, indicate that although hepcidin regulation by iron stores is maintained in CHC, the suppression of this hormone by hepatitis C virus is likely an important factor in liver iron accumulation in this condition.

Abbreviations: CHC, chronic hepatitis C, HCV, hepatitis C virus, ANOVA, analysis of variance, CV, coefficient of variation, CIs, confidence intervals, CRP, C-reactive protein, ELISA, enzyme-linked immunosorbent assay, ESR, erythrocyte sedimentation rate, HFE, haemochromatosis type 1 gene, HBV, hepatitis B virus, HCC, hepatocellular carcinoma, mRNA, messenger RNA, ROS, reactive oxygen species, SELDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry assay, TIS, total iron score, TS, transferrin saturation

Keywords: Chronic hepatitis C, Hemochromatosis, Hepcidin, Iron overload, Ferritin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by NIH (Grant Nos. DK065029 to T.G., K01 DK075378 to E.N., and F30 DK082151 to J.G.). T.G. and E.N. are co-founders and officers of Intrinsic Life Sciences, LLC. The other authors declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00520-0

doi:10.1016/j.jhep.2009.06.027

Journal of Hepatology
Volume 51, Issue 5 , Pages 845-852, November 2009